Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 성연아 | * |
dc.date.accessioned | 2016-08-28T10:08:27Z | - |
dc.date.available | 2016-08-28T10:08:27Z | - |
dc.date.issued | 2013 | * |
dc.identifier.issn | 1368-5031 | * |
dc.identifier.other | OAK-9764 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/223436 | - |
dc.description.abstract | Aim:s: The study investigated the clinical equivalence in reducing haemoglobin A1c (A1C) between glimepiride/metformin sustained release (GM-SR) 2/500 mg, a fixed-dose combination, once daily and glimepiride/metformin (GM) 1/250 mg, a fixed-dose combination, twice daily in patients with type 2 diabetes (T2D). Methods: A multicentre, randomised, double-blind, double-dummy study was conducted in 14 hospitals in Korea. Inclusion criteria were age 30-75 years, T2D diagnosis no longer than 10 years previously, A1C between 7% and 10%, and body mass index < 40 kg/m2. A total of 207 subjects were randomised into the GM-SR group (n = 101) or the GM group (n = 106). Participants were assessed at baseline, 8 weeks and 16 weeks after treatment. Results: After 16 weeks treatment, no difference in baseline-adjusted changes of A1C (primary efficacy variable) was observed between the two groups (-0.59% for GM-SR group vs. -0.61% for GM group, 95% CI: -0.17 to 0.21; p = 0.84). In addition, there were no significant differences in secondary efficacy parameters between the two groups, including changes in A1C up to week 8, changes in fasting plasma glucose (FPG) and 2-h-postprandial plasma glucose up to week 8 and week 16, response rate, drug compliance and hypoglycaemic events. However, there was a difference in baseline-adjusted changes of FPG between the two groups (-1.01 mmol/l for GM-SR group vs. -1.52 mmol/l for GM group, p = 0.01 in the intention to treat set). Conclusions: GM-SR 2/500 mg once daily was as effective as GM 1/250 mg twice daily in lowering A1C. In addition, no difference was noted in hypoglycaemic events between the two groups. © 2013 Blackwell Publishing Ltd. | * |
dc.language | English | * |
dc.title | Efficacy and safety of glimepiride/metformin sustained release once daily vs. glimepiride/metformin twice daily in patients with type 2 diabetes | * |
dc.type | Article | * |
dc.relation.issue | 3 | * |
dc.relation.volume | 67 | * |
dc.relation.index | SCI | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.startpage | 236 | * |
dc.relation.lastpage | 243 | * |
dc.relation.journaltitle | International Journal of Clinical Practice | * |
dc.identifier.doi | 10.1111/ijcp.12071 | * |
dc.identifier.wosid | WOS:000315117700009 | * |
dc.identifier.scopusid | 2-s2.0-84874113416 | * |
dc.author.google | Hwang Y.-C. | * |
dc.author.google | Kang M. | * |
dc.author.google | Ahn C.W. | * |
dc.author.google | Park J.S. | * |
dc.author.google | Baik S.H. | * |
dc.author.google | Chung D.J. | * |
dc.author.google | Jang H.C. | * |
dc.author.google | Kim K.-A. | * |
dc.author.google | Lee I.-K. | * |
dc.author.google | Min K.W. | * |
dc.author.google | Nam M. | * |
dc.author.google | Park T.S. | * |
dc.author.google | Son S.M. | * |
dc.author.google | Sung Y.-A. | * |
dc.author.google | Woo J.-T. | * |
dc.author.google | Park K.S. | * |
dc.author.google | Lee M.-K. | * |
dc.contributor.scopusid | 성연아(18435369300) | * |
dc.date.modifydate | 20240118125434 | * |